These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 29356692

  • 1. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
    Wei Y, Zhou F, Lin Z, Shi L, Huang A, Liu T, Yu D, Wu G.
    Anticancer Drugs; 2018 Mar; 29(3):262-270. PubMed ID: 29356692
    [Abstract] [Full Text] [Related]

  • 2. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [Abstract] [Full Text] [Related]

  • 3. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R, Zhang R, Zhang S, Wu G.
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [Abstract] [Full Text] [Related]

  • 4. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
    Liu Y, Tong Y, Yang X, Li F, Zheng L, Liu W, Wu J, Ou R, Zhang G, Hu M, Liu Z, Lu L.
    Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
    [Abstract] [Full Text] [Related]

  • 5. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
    Lee TG, Jeong EH, Kim SY, Kim HR, Kim CH.
    Int J Cancer; 2015 Jun 01; 136(11):2717-29. PubMed ID: 25382705
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    Breast Cancer Res; 2015 Mar 07; 17():33. PubMed ID: 25888415
    [Abstract] [Full Text] [Related]

  • 7. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.
    PLoS One; 2010 Sep 14; 5(9):e12417. PubMed ID: 20856855
    [Abstract] [Full Text] [Related]

  • 8. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR, Han BR, Park WH.
    Oncotarget; 2017 Mar 14; 8(11):17726-17737. PubMed ID: 28099148
    [Abstract] [Full Text] [Related]

  • 9. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.
    Mol Cancer Ther; 2009 Jun 14; 8(6):1596-605. PubMed ID: 19509267
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM, Tang YA, Hu FH, Huang WJ, Wang YJ, Jen J, Liao SY, Lu YH, Yeh YL, Wang TW, Lin P, Wang YC.
    Int J Cancer; 2017 May 15; 140(10):2375-2386. PubMed ID: 28233309
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.
    Clin Cancer Res; 2006 Sep 01; 12(17):5199-206. PubMed ID: 16951239
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T, Prasad R, Katiyar SK.
    Epigenetics; 2013 Jan 01; 8(1):54-65. PubMed ID: 23221619
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP.
    Oncol Rep; 2006 Jan 01; 15(1):187-91. PubMed ID: 16328054
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.